Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo®): Profile report

Pediatric Drugs

Volumn 14, Issue 1, 2012, Pages 63-65

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Profile Reports; Adolescents; Adults; Meningococcal infections; Meningococcal vaccine groups A C Y W 135 conjugate

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ARTICLE; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MENINGITIS; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEISSERIA; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; SURVIVAL RATE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; RESEARCH REPORT; VACCINES, CONJUGATE;

EID: 83455258186     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11206930-000000000-00000     Document Type: Article

References (20)

1. Deeks ED. Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo-): In adults and adolescents.Biodrugs 2010; 24 (5): 287-97
2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, andNeisseriameningitidis.Lancet 2007 Jun 30; 369 (9580): 2196-210
3. Reisinger KS, Black S, Stoddard JJ. Optimizing protection against meningococcal disease. Clin Pediatr (Phila) 2010 Jun; 49 (6): 586-97
4. Hill DJ, Griffiths NJ, Borodina E, et al. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond) 2010 Feb 9; 118 (Pt 9): 547-64
5. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009 Jun 24; 27 Suppl. 2: B51-63
6. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001 May 3; 344 (18): 1378-88
7. Bröker M, Dull PM, Rappuoli R, et al. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009 Sep 18; 27 (41): 5574-80
8. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009 Dec; 16 (12): 1810-5
9. Sanofi Pasteur Inc. Meningococcal (groupsA,C,Yand W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra-: US prescribing information [online]. Available from URL: Http://www.fda.gov/downloads/BiologicsBlood Vaccines/Vaccines/ApprovedProducts/UCM131170.pdf [Accessed 2010 Apr 26]
10. Sanofi Pasteur Inc. Menactra-(meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine): Canadian prescribing information [online]. Available from URL: Http://www.menactra.ca/User Files/File/Menactra-HCP-EN.pdf [Accessed 2010 Apr 26]
11. Advisory Committee on Immunization Practices. Report from the Advisory Committee on Immunization Practices (ACIP): Decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008 May 2; 57 (17): 462-5
12. Novartis Vaccines and Diagnostics Inc. Menveo-(meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) solution for intramuscular injection: US prescribing information [online]. Available from URL: Http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM201349.pdf [Accessed 2010 Apr 16]
13. Novartis Vaccines. Menveo group A, C, W135 and Y conjugate vaccine: UK summary of product characteristics [online]. Available from URL: Http://www.medicines.org.uk [Accessed 2010 Apr 20]
14. Advisory Committee on Immunization Practices. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use: Advisory Committee on Immunization Practices (ACIP), 2010.MMWRMorb Mortal Wkly Rep 2010 Mar 12; 59 (9): 273
15. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009 Feb; 28 (2): 86-91
16. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009 Jul 1; 49 (1): E1-10
17. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. Epub 2010 Jul 21
18. Gill C, Kleinschmidt A, Anemona A, et al. Antibody persistence 22 months after vaccination of adolescents with the Menveo-conjugate vaccine or Menactra-. Poster presented at the 14th International Congress on Infectious Diseases; 2010 Mar 9-12; Miami (FL)
19. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010 Apr; 17 (4): 537-44
20. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28 (18): 3171-9